SLXNW Silexion Therapeutics Ltd.
Healthcare$0.02-5.14%ClosedMarket Cap: $9,312
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
5.55
P/S
0.00
EV/EBITDA
0.13
DCF Value
$3.59
FCF Yield
-4283.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-516.9%
ROA
-280.5%
ROIC
1448.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-2.7M | $-2.7M | $— | — |
| Q4 null | $0.00 | NaN% | $18.9M | $-4.4M | $— | — |
| FY null | $0.00 | NaN% | $11.6M | $-11.9M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-3.3M | $-3.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.3M | $-2.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.6M | $-1.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-23.2K | $-31.1K | $— | — |
| FY null | $0.00 | NaN% | $-12.6M | $-16.4M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-8.0M | $-11.9M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-1.4M | $-1.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.3M | $-1.4M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-1.7M | $-1.7M | $-0.67 | — |